Jump to content

Yttrium (90Y) tacatuzumab tetraxetan

From Wikipedia, the free encyclopedia
Yttrium (90Y) tacatuzumab tetraxetan
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetα-fetoprotein
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6470H9971N1712O2007S4290Y
Molar mass145 kg/mol
 ☒NcheckY (what is this?)  (verify)

Yttrium (90Y) tacatuzumab tetraxetan is an investigational humanized monoclonal antibody intended for the treatment of cancer.[1] The antibody itself, tacatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90,[2] a radioisotope which destroys the tumour cells.

References

[edit]
  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council". 4 September 2004. Archived from the original on 2004-09-11.
  2. ^ WHO Drug Information